Abstract
Background: High levels of LDL cholesterol were directly related to the risk of atherosclerosis, metabolic diseases, and cardiovascular complications. However, in some groups of patients with low levels, they were also found. Lead to the risk of other lipid components, including Remnant cholesterol. A recent study found related to cardiovascular risk as well. Currently, no direct comparison between Remnant cholesterol and LDL cholesterol level.
Objective: To study the correlation between Remnant cholesterol and LDL levels both in fasting and non-fasting states with the medical conditions that increase the risk of cardiovascular disease.
Materials and methods: To determine the association between remnant cholesterol and LDL. 200 cases of Thai begins at the age of 18 years old were tested for total cholesterol, LDL, HDL, and TG level both in the fasting and non-fasting states. The obtained values were calculated for Remnant cholesterol levels and analysed for a direct correlation between the two levels, which also includes a comparative analysis. The AUC was used to assess the prognostic accuracy of lipid levels to diagnose the condition that poses cardiovascular risks.
Results: In the sample of 200 patients tested for lipid. At a mean age of 64.5 years, 42 percent were female and 76.5 percent received statins. We found that remnant cholesterol had a poor correlation with LDL levels when compared among the fasting conditions (r=0.164, 0.119), as well as among the statin used or not (r=0.118, 0.293). The analysis found that remnant cholesterol does well correlate with TG levels (r=0.770). Also, the predictive value of Remnant cholesterol over LDL levels for detect diabetes mellitus, coronary artery disease, and overweight (AUC=0.610, 0.588, 0.593).
Conclusion: In this study. We found that remnant cholesterol does correlate poorly with LDL in any fasting state. Prediction of the incidence of diabetes mellitus, coronary heart disease, and overweight has seemed better with remnant cholesterol. More studies may need for decreasing the knowledge gap and provide a better guide for disease prevention.
Keywords
References
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 290:140-205, 2019.Google Scholar ↗
- GrundySM,StoneNJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:e1082-e1143, 2019.Google Scholar ↗
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 140:e596-e646, 2019.Google Scholar ↗
- Ference BA, Ginsberg HN, Graham I, et al. Lowdensity lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38:2459-2472, 2017.Google Scholar ↗
- Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 105:1424-1428, 2002.Google Scholar ↗
- Fernandez-Friera L, Fuster V, Lopez-Melgar B, Oliva B, Garcia-Ruiz JM, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. J Am Coll Cardiol 70:2979-2991, 2017.Google Scholar ↗
- Feig JE, Hewing B, Smith JD, et al. High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ Res 114:205-213, 2014.Google Scholar ↗
- Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 23:1724-1731, 2003.Google Scholar ↗
- Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, et al. HDL Cholesterol, Very Low Levels of LDL Cholesterol and Cardiovascular Events. 357:1301-1310, 2007.Google Scholar ↗
- Di Bartolo BA, Psaltis PJ, Bursill CA, et al. SJ Translating Evidence of HDL and Plaque Regression. Arterioscler Thromb Vasc Biol 38:1961-1968, 2018.Google Scholar ↗
- Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. European Heart Journal Supplements 7:4-8, 2005.Google Scholar ↗
- Marston NA, Giugliano RP, Stroes ES, et al. Abstract 15703: Prognostic Value of Elevated Triglycerides in Atherosclerotic Disease. 138:15703, 2018.Google Scholar ↗
- Dron JS, Hegele RA. Genetics of Triglycerides and the Risk of Atherosclerosis. Curr Atheroscler Rep 19:31, 2017.Google Scholar ↗
- Ohmura H. Triglycerides as Residual Risk for Atherosclerotic Cardiovascular Disease. Circ J 83:969-970, 2019.Google Scholar ↗
- Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 13:544-552, 2011.Google Scholar ↗
- Puri R, Nissen SE, Shao M, et al. Non HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. Arterioscler Thromb Vasc Biol 36:2220-2228, 2016.Google Scholar ↗
- Vega GL, Grundy SM. Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. J Clin Lipidol 13:563-567, 2019.Google Scholar ↗
- Nordestgaard BG, Langsted A, Mora S, et al. Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cut points-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem 62:930-946, 2016.Google Scholar ↗
- Dogan C, Tasar O, Bayram Z, et al. Increased Remnant Cholesterol Blood Concentration Associated with First Acute Coronary Syndrome. Kosuyolu Heart J 22:69-73, 2019.Google Scholar ↗
- Jepsen AM, Langsted A, Varbo A, et al. Increased Remnant Cholesterol Explains Part of Residual Risk of All Cause Mortality in 5414 Patients with Ischemic Heart Disease. Clin Chem 62:593-604, 2016.Google Scholar ↗
- Wurtz P, Kangas AJ, Soininen P, et al. Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. J Am Coll Cardiol 62:1906-1908, 2013.Google Scholar ↗
- McPherson R. Remnant cholesterol: "Non-(HDL-C + LDL-C)" as a coronary artery disease risk factor. J Am Coll Cardiol 61:437-439, 2013.Google Scholar ↗
- Saeed A, Feofanova EV, Yu B, et al. Remnant Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides and Incident Cardiovascular Disease. J Am Coll Cardiol 72:156-169, 2018.Google Scholar ↗
- Joshi PH, Martin SS, Blumenthal RS. The Remnants of Residual Risk. J Am Coll Cardiol 65:2276-2278, 2015.Google Scholar ↗
- Hong LF, Yan XN, Lu ZH, et al. Predictive value of non-fasting remnant cholesterol for short-term outcome of diabetics with new-onset stable coronary artery disease. Lipids Health Dis 16:7, 2017.Google Scholar ↗